Boundless Bio (BOLD)
Wind-down-stage ecDNA oncology developer pursuing a merger with Serapha Bio.
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Boundless Bio, Inc. (NASDAQ: BOLD ) related to its merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages Boundless Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. “We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based therapies for central nervous system injuries, is pleased to announce that it received first place in the Healthcare category at the BOLD Awards VII Gala held in Barcelona on March 27, 2026 and provides corporate update.
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.
NurExone Announces Corporate Updates
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing
DOT'S® INTRODUCES DOT'S ORIGINAL SNACK MIX - A BOLD NEW TAKE ON SNACKING
Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options.
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026.
BUBBA® UNVEILS A BOLD, NEW BRAND IDENTITY AND NEXT-GEN WATER BOTTLE DESIGNS, TURNING EVERYDAY HYDRATION INTO PERSONAL EXPRESSION
It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold Colorways, Transform Hydration into a Statement Piece ATLANTA, Jan. 14, 2026 /PRNewswire/ -- Today, bubba® , part of Newell Brands' global portfolio and an emerging leader in oversized, high-performance water bottles, announces a bold evolution of its brand identity alongside the launch of a new generation of reuseable water bottle designs.
21shares launches BOLD ETP combining bitcoin and gold in a single regulated product
Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong.
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in New York, NY, at 9:30 a.m.
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended September 30, 2025. “We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with oncogene-amplified cancers,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio will be presenting upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
BLOOMINGDALE'S UNVEILS BOLD FALL 2025 CAMPAIGN: JUST IMAGINE
An immersive celebration of art, identity, and modern retail arrives this fall at Bloomingdale's 59th Street flagship—featuring a striking façade and Carousel takeover, designed by acclaimed artist Yinka Ilori NEW YORK , Sept. 4, 2025 /PRNewswire/ -- This fall, Bloomingdale's redefines the retail experience with Just Imagine—a bold, boundary-pushing campaign that transforms the iconic department store into a dynamic museum where fashion, art, and immersive storytelling converge.
PRINGLES® IS BRINGING BOLD NEW FLAVORS TO THE SNACK AISLE WITH SIX SMOKY, SALTY AND SWEET INNOVATIONS
Introducing New Pringles Smoky lineup, Pringles Sharp White Cheddar, Pringles Mingles Cinnamon & Sugar and Jalapeño & Queso, plus a unique opportunity to give one flavor a first try KEY POINTS: Pringles is bringing six bold new flavors to the snack aisle including: Three new flavors from a new Pringles Smoky collection, Pringles Sharp White Cheddar, Pringles Mingles Cinnamon & Sugar and Pringles Mingles Jalapeño & Queso. To celebrate, Pringles is teaming up with Chef Calvin Eng and his restaurant Bonnie's to create a one-of-a-kind dish featuring Pringles Smoky Mesquite BBQ.